Effect of camouflaging agents on psychologic well-being: A cross-sectional survey of hair loss patients To the Editor: Pattern hair loss is common in the general population, affecting 50% of men by age 50 1 and 30% of women by age 30, 2 with prevalence increasing with age. Despite the high prevalence, few treatment options with established safety and efficacy are available. Topical minoxidil, oral finasteride, anti-androgen therapy are commonly used 1 but require indefinite use and rarely accomplish complete regrowth, leaving many patients dissatisfied. 3 Hair loss is associated with substantial psychological distress that is particularly severe for women. In a study of 60 men and 96 women with pattern hair loss, 52% of women and 27% of men were very to extremely upset about their hair loss. 3 There is a paucity of information regarding topical camouflaging agents used to conceal hair loss. To the authors' knowledge, there is only one study of 40 patients investigating the effect of these products on patients' confidence, which was reported to improve. 4 In the present study, we sought to better understand the use of these products and their impact on patients' appearance and self-esteem.
A link to a 12-query, anonymous, IRBapproved survey, created using Survey Monkey, was posted on various Internet hair loss blogs. Individuals completed the survey voluntarily and were included if they were at least 18 years old with self-reported hair loss. In total, 359 individuals responded. Of these, 348 (97%) reported hair loss, and 281 (78%) had seen a physician about their hair loss. Camouflaging agents were used by 283 (79%), and the products chosen were most often hair-building fibers (59%), followed by hairpieces and wigs (51%). Forty-three percent used topical concealing agents daily. Use of these products improved appearance in 216 (82%) respondents, and 173 (71%) reported improved selfesteem.
Patients gave 316 responses to open-ended questions asking about their topical concealer experiences and preferences. Topical concealers worked well for minimal-to-moderate hair loss, but a hairpiece was preferred as hair loss progressed. Negative aspects of topical concealers were messiness ( particularly on clothing, bedding, and bathroom surfaces), time for application, expense, itchiness, anxiety over concealers being conspicuous or unnatural looking, and the removing effects of wind, rain, and swimming. Many believed the positive effects on appearance and self-confidence outweighed these negative aspects.
Although most respondents saw a physician for hair loss, only 8 of 270 respondents (3%) reported learning about concealing products from their physician. We attempted to contact 20 regional dermatologists specializing in hair loss to ascertain if these products were recommended; only 4 responded, and none recommended these products, confirming our results. This experience further suggests that patients might have difficulty obtaining information before or after an appointment.
Products to conceal hair loss are readily available online from dozens of retailers. Table I provides information about types of products and their cost. 5 Pattern hair loss is one of the most common chronic problems encountered by dermatologists. 1 Given the significant psychologic morbidity in patients with hair loss and the limited effective treatment options, the authors believe that physicians should educate their patients about topical concealing agents, which can serve as an adjunct to medical therapy and improve psychologic well-being.
Limitations of this study include the potential for survey bias and recall bias from self-reporting patients. Research Letters 1187 Apremilast in the treatment of moderate to severe hidradenitis suppurativa: A case series of 9 patients
To the Editor: Despite the many therapeutic approaches available for hidradenitis suppurativa, there is still a need for effective medications to treat moderate and severe forms of the disease. In this study, we assessed the efficacy of the oral phosphodiesterase 4 inhibitor apremilast (30 mg, twice a day) in the management of 9 patients with moderate to severe hidradenitis suppurativa (Hurley stage II-III) who had responded poorly to other treatments. The treatment was assessed using Sartorius score clinical staging, visual analog scale (VAS) for pain, and Dermatology Life Quality Index (DLQI) scores before therapy and 2 to 3 months after induction. Three patients ( patients 7, 8, and 9 in Table I ) failed to continue treatment because of reflux, preexisting depression, and problems with health insurance. Of the remaining 6 patients (mean age, 44.33 6 13.54 years; 5 smokers), 5 showed a promising response, which was shown by a significant improvement in mean 6 standard deviation Sartorius score clinical staging of 73.17 6 67.76 to 56.17 6 44.89 (P ¼ .028; Table I ). A representative patient is shown in Fig 1 (see page 1191) .
Patients reported a mean 6 standard deviation pain VAS score of 7.17 6 0.98 before treatment and 2.00 6 2.10 after therapy, indicating a significant decrease in pain (P ¼ .026). Pain is one of the major symptoms reported by patients with hidradenitis suppurativa and the biggest source of reduced quality of life.
1 This is also shown in the current study by the significant positive correlation between DLQI and VAS pain score in the Spearman correlation coefficient (P ¼ .021, r ¼ 0.655). Most patients added that they were able to cope better with their disease after therapy, as shown by the DLQI, which improved significantly from 21.33 6 8.91 to 9.33 6 5.85 (P ¼ .027).
Although it has many antiinflammatory effects, the mechanism by which apremilast may work in hidradenitis suppurativa is unknown. However, therapy with a phosphodiesterase 4 inhibitor, such as apremilast, which can modulate key pro-and antiinflammatory mediators, such as tumor necrosis factore, interleukin-23 (IL) and IL-12 and chemoattraction via regulation of IL-8 and interferon-einduced protein 10 expression, might suppress the cellular mechanisms involved and expression of many upregulated cytokines in hidradenitis suppurativa. [1] [2] [3] [4] [5] Limitations of this study include its small sample size and short duration. However, the promising results and good tolerability we observed suggest that apremilast may have a role in treatment of moderate to severe hidradenitis suppurativa. We hope that larger, controlled clinical trials will further elucidate the potential role of apremilast for this challenging disease.
